European Commission · September 07, 2025

HTA Regulation: Joint Clinical Assessments mandatory for cancer medicines and ATMPs

Original title: HTA Regulation - Cancer and ATMPs

Joint Clinical Assessments become mandatory for new cancer medicines and advanced therapy medicinal products under HTA Regulation.

High obligation Sector Pharmaceuticals Market Access & Reimbursement EU-wide PharmaceuticalsHealth technology assessmentReimbursement

Joint Clinical Assessments become mandatory for new cancer medicines and advanced therapy medicinal products

Dates and deadlines

Enters Force

January 12, 2025

Read the official source ↗

Published by European Commission. HealthSignal links to the original document; the summary above is extracted from the source text.